All Episodes – Page 4
Browse our complete library of interviews and discussions with leading experts in oncology.

Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial
This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding…

AUDIO JOURNAL OF ONCOLOGY PM 2.5 Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer
An Audio Journal of Oncology episode reports on research linking particulate air pollution (PM 2.5) to non-small cell lung cancer in never smokers. Professor Charles Swanton's group identified…

Wojciech Jurczak MD PhD; ASH 2025: Big Study Suggests Non-Covalent BTK Inhibitor Pirtobrutinib Could be New Standard-of-Care for Patients with Untreated Chronic Lymphocytic Leukemia
Wojciech Jurczak MD PhD discusses research from ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is superior to bendamustine plus rituximab as initial therapy for untreated…

Gaorav Gupta MD PhD; SABCS 2025: Pre-Op Radiation Improved T-cell Infiltration in Hormone Receptor-positive, HER2-negative Invasive Breast Cancer; Could Boost Systemic Therapy Responses
At SABCS 2025, Gaorav Gupta MD PhD presented findings from the TBCRC-053 (P-RAD) study. The research showed that pre-operative radiation therapy significantly increased T-cell infiltration in hormone…

Lorenzo Falchi MD; ASH 2025: Bispecific Antibody Epcoritamab Combination Beats Standard of Care for Patients with Relapsed/Refractory Follicular Lymphoma
This episode discusses how the bispecific antibody Epcoritamab, in combination with rituximab and lenalidomide, has outperformed standard treatment for relapsed/refractory follicular lymphoma in the…

Christian F. Singer MD; 2025 SABCS: Denosumab Bone Protection in ER-Positive Early Breast Cancer Brings Added Benefit with Progesterone Receptor Positive Tumors: ABCSG 18 Study Findings
Dr. Christian F. Singer discusses findings from the ABCSG 18 Study at the 2025 San Antonio Breast Cancer Symposium. The research indicates that post-menopausal women with ER-positive early breast…

Amir Fathi MD; ASH 2025: Paradigm Study Finds Young, Fit Adults with Acute Myeloid Leukemia Do Better with Gentler Azacitidine/Venetoclax Initial Therapy
An interview with Amir Fathi MD from Massachusetts General Hospital discusses the Paradigm study presented at ASH 2025. The phase two randomized trial found that young, fit adults with acute myeloid…

Jennifer A. Woyach MD, ASH 2024: The Non-Covalent Bruton’s Tyrosine Kinase-Inhibitor Pirtobrutinib is As Effective, While Less Toxic, In Relapsed/Refractory Chronic Lymphocytic Leukemia
Dr. Jennifer A. Woyach discusses promising phase III study findings at ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is as effective as ibrutinib, while demonstrating less…

Alexis Ann LeVee MD; 2025 SABCS: Pre-Operative Gut Microbiome Predicts Complete Response to Immune Checkpoint Inhibition in Patients with Early-stage HER2-positive Breast Cancer
Alexis Ann LeVee MD presented novel research at the 2025 San Antonio Breast Cancer Symposium. Her team's study, the randomized phase II neoHIP trial, revealed that pre-operative gut microbiome…

Meletios Dimopoulos; ASH 2025: B-Cell Maturation Antigen Bispecific Antibody Linvoseltamab Brings High Response Rates in Patients with Relapsed/Refractory Multiple Myeloma
Meletios Dimopoulos MD, Chair of Clinical Therapeutics at the University of Athens, discusses early findings from the phase 1b LINKER-MM2 trial presented at ASH 2025. The study reveals high clinical…

Antonio Jimenez Jimenez MD MS; ASH 2025: Donor Choice No Longer a Barrier to Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies
Antonio Jimenez Jimenez MD MS, from the University of Miami, presented findings at ASH 2025 indicating that donor choice is less of a barrier to allogeneic stem cell transplantation for patients with…

Safna Naozer Virji MBBS FPBS; 2025 SABCS: Oncoplastic Breast Cancer Surgery Study Reports High Efficacy with Superior Psychosocial Outcomes in a Low or Middle Income Country Setting
Safna Naozer Virji MBBS FPBS was interviewed at the 2025 San Antonio Breast Cancer Symposium regarding her study on oncoplastic breast cancer surgery. Her research from Pakistan reported high…

Luciano Costa, MD PhD; ASH 2025: CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard-Risk Relapsed/Refractory Multiple Myeloma
Dr. Luciano Costa discusses the findings from the CARTITUDE-4 study at the ASH 2025 Annual Meeting in Orlando. The study demonstrates that ciltacabtagene autoleucel CAR-T cell therapy provides…

Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer
Matteo Lambertini MD PhD discusses new findings from the ALTTO trial at the 2025 San Antonio Breast Cancer Symposium. The long-term analysis reveals that adjuvant aromatase inhibitors lead to…

Jesse Tettero MD PhD; ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia
Dr. Jesse Tettero discusses findings from the HARMONY Alliance study, presented at ASH 2025, validating measurable residual disease (MRD) as a robust predictor of overall survival in acute myeloid…

Hisham Abdel-Azim MD MS; ASH 2025: Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation
Dr. Hisham Abdel-Azim discusses findings from the phase two EndRAD trial, presented at ASH 2025. The study reveals that Next Generation Sequencing-Assessed Minimum Residual Disease (NGS-MRD) can…

Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer

Daniel J Zheng MD, MHS, MSHP; ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! “Financial Toxicity” is Often More Worrying than your Child’s Cancer
Financial Disaster from curative treatment for childhood ALL

Peihua Lu MD and Robert Chiesa MD PhD; ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies
Dramatic Cures for Children with No Prospects Using Standard Therapies for T-cell malignancies

Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f